Video & Multimedia
Related: About this forumBigDemVoter
(4,149 posts)We don't know yet what kind of results we will have. . .
MartyTheGreek
(565 posts)Last edited Thu Apr 16, 2020, 06:58 PM - Edit history (1)
Look here not there...
Joe Grogan, a former lobbyist for Gilead Sciences: https://truthout.org/articles/ex-pharma-lobbyist-embedded-in-white-house-tanked-drug-pricing-bill/
REF: From Wiki Gilead, Inc. "On January 21 2020, the Wuhan Institute of Virology applied for a Chinese "use patent" on remdesivir, for the novel use of treating COVID-19.[73]"
"China abruptly and recently stops 2 Remdesivir studies: Gilead previously confirmed that enrollment in that study has been halted. Evercore ISI analyst Umer Raffat told investors in a note on Wednesday that the large number of trials initiated in China to find a treatment for the disease may have made it difficult to find enough participants. However, he also noted that: "We can't ignore the fact that if remdesivir had overwhelming efficacy, trials may have enrolled." Last week Gilead published the first batch of data examining the response to remdesivir in patients with COVID-19 who had received the drug on a compassionate-use basis. Gilead's stock is up 14.7% year-to-date."
Many drug studies are stopped when they show strong effectiveness and little harm too.
https://www.marketwatch.com/story/gileads-stock-drops-after-china-halts-second-remdesivir-trial-2020-04-15?mod=mw_quote_news
Warpy
(111,166 posts)and I imagine they're ongoing at other teaching hospitals, as well.
Seems I was right in my leap of illogic that said the antiviral effect of quinine drugs was dose related, and patients were injured or outright killed by the necessary dosage. I also don't know why they gave antibiotics with it, those do zip against viruses, although they're given to prevent bacterial superinfection in people with bad viral pneumonia.
Antiviral drugs make a lot more sense.